Remote monitoring program for managing high blood pressure during virtual care
Evaluating the Use of a Remote Telehome Monitoring and Management Hypertension Program for Patients Receiving Virtual Care: A Pilot Randomized Controlled Trial
This study is testing a remote program to help people with high blood pressure manage their condition from home while getting virtual care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ottawa Heart Institute Research Corporation Academic / other |
| Locations | 1 site (Ottawa, Ontario) |
| Trial ID | NCT05300503 on ClinicalTrials.gov |
What this trial studies
This study evaluates a telehome monitoring program designed for patients with hypertension who are receiving virtual care. It aims to assess how effectively patients can monitor their blood pressure at home, especially during the COVID-19 pandemic when in-person visits are limited. The program will provide patients with the necessary tools and support to manage their hypertension remotely, ensuring they receive appropriate medication adjustments based on their readings. The study will also explore barriers patients face in using home blood pressure monitoring devices.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with primary hypertension who have access to a phone and a 4G cellular network at home.
Not a fit: Patients actively managed at specialized hypertension clinics or those who are pregnant or institutionalized may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could improve blood pressure management for patients receiving virtual care, leading to better health outcomes.
How similar studies have performed: Other studies have shown promise in using telehealth and remote monitoring for chronic conditions, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have a diagnosis of primary, essential HTN (SBP\>140/90mmHg or \>130/80mmHg for diabetes) * Have access to a phone (can be a landline) * Have access to cellular (4G) network at their primary residence (they do not need to physically own a cellular phone but the need to be able to confirm their residence has 4G network access in order to connect the Aetonix aTouchAway platform to the network) * Speak English or French Exclusion Criteria: * Patients who have been referred or who are actively managed at a specialized HTN clinic or other Telehome monitoring program * Women who are pregnant, breastfeeding or planning to become pregnant * Patients who are institutionalized at a retirement home, nursing home or long-term care facility * Patients who plan on travelling out of the country for more than 2 weeks at any point during the intervention phase of the study (first 3 months) * Patients who are cognitively impaired or experiencing acute psychiatric illness that would alter their ability to participate
Where this trial is running
Ottawa, Ontario
- The University of Ottawa Heart Institute — Ottawa, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Hassan Mir, MD — Ottawa Heart Institute Research Corporation
- Study coordinator: Ashley Baldwin
- Email: asbaldwin@ottawaheart.ca
- Phone: 613-696-7000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.